Open Access<p>Characterization and bioactivity of self-assembled anti-angiogenic chondroitin sulphate-ES2-AF nanoparticle conjugate</p>
Author(s) -
Xizhuang Liang,
Feng Sun,
Zhendong Wang,
Yan Li,
Zhifang Yang,
Fengshan Wang,
Guangxi Zhai,
Haining Tan
Publication year - 2019
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s195934
Subject(s) - conjugate , nanoparticle , chondroitin sulfate , chondroitin sulphate , chemistry , angiogenesis , chondroitin , materials science , biophysics , glycosaminoglycan , nanotechnology , biochemistry , cancer research , medicine , biology , mathematical analysis , mathematics
In the past few years, significant progress has been made in inhibiting neovascularization at the tumor site, cutting off the nutrient supply of the tumor, and inhibiting tumor growth and metastasis. However, many proteins/peptides have the disadvantage of poor stability, short half-life, and uncertain targeting ability. Chemical modification can be used to overcome these disadvantages; many polyethylene glycol-modified proteins/peptides have been approved by US FDA. The purpose of this study was to obtain a novel anti-angiogenic chondroitin sulfate (CS)-peptide nanoparticle conjugate with efficient anti-neovascularization and tumor targeting ability and an acceptable half-life.